Survival by Treatment Groups and Presence of Liver Metastases
Error bars indicate 90% CIs. BSC indicates best supportive care.On univariable analysis, there were no differences in OS between the durvalumab plus tremelimumab and BSC groups, regardless of LM, and a test of interaction was negative. Progression-free survival was improved with in the durvalumab plus tremelimumab group among patients without LM (HR, 0.54 [90% CI, 0.35-0.96]; 